收藏切换
Recommendations on clinical treatment of heart failure with Chinese patent medicines
收藏切换
PDF
Zi-ru LI1, Shi-hao NI1, Xin DONG2, Xiao-wei HAN1, Xiao-jiao ZHANG1, Si-jing LI1, Lu LU2, Shao-xiang XIAN2, Zhong-qi YANG2
Chinese Journal of New Drugs | 2023, 32(4) : 348 - 356
Less
收藏切换
Chinese Journal of New Drugs | 2023, 32(4): 348-356
Recommendations on clinical treatment of heart failure with Chinese patent medicines
Full
Zi-ru LI1, Shi-hao NI1, Xin DONG2, Xiao-wei HAN1, Xiao-jiao ZHANG1, Si-jing LI1, Lu LU2, Shao-xiang XIAN2, Zhong-qi YANG2
Affiliations
  • 1Guangzhou University of Chinese Medicine, Guangzhou 510405, China
  • 2The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510407, China
Published: 2023-02-28
Outline
收藏切换

To provide recommendations for clinicians on rational use of Chinese patent medicine for treatment of heart failure, the study was conducted by systematically collecting and analyzing clinical randomized controlled trials (RCTs). Based on three international electronic databases (PubMed, Embase and Cochrane library) and three Chinese literature databases (Chinese Journal Full Text Database, Wanfang Medical Database and Chinese Science and Technology Journal Database (Weipu)), all relevant RCTs from the beginning of the establishment of each database to July 1, 2022 were included, a total of 83 proprietary Chinese medicines were retrieved, and finally 15 proprietary Chinese medicines were chosen to be recommended for treatment of heart failure, including 7 injections and 8 oral proprietary Chinese medicines. The basic information, sample size, intervention and outcome indicators of the 15 proprietary Chinese medicines were compared and analyzed, and the quality of evidence for the efficacy of the included proprietary Chinese medicines was evaluated using the GRADE classification method to assess their efficacy and safety on heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF) and acute heart failure (AHF). Combined with the evidence-based medicine approach, a comprehensive evaluation of 15 proprietary Chinese medicines currently in use and with sufficient evidence for the treatment of heart failure were conducted, with the intention to provide some basis for clinicians to use proprietary Chinese medicines rationally.

Chinese patent medicine  /  heart failure  /  evidence-based medicine  /  medication recommendation
Zi-ru LI, Shi-hao NI, Xin DONG, Xiao-wei HAN, Xiao-jiao ZHANG, Si-jing LI, Lu LU, Shao-xiang XIAN, Zhong-qi YANG. Recommendations on clinical treatment of heart failure with Chinese patent medicines[J]. Chinese Journal of New Drugs, 2023 , 32 (4) : 348 -356 .
Year 2023 volume 32 Issue 4
PDF
25
5
Cite this Article
BibTeX
Article Info
  • Online Date:2026-03-05
  • Published:2023-02-28
Article Data
Affiliations
History
  • Accepted:2022-09-26
Funding
Affiliations
    1Guangzhou University of Chinese Medicine, Guangzhou 510405, China
    2The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510407, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT